塞利尼索联合多柔比星治疗晚期软组织肉瘤的1b期试验
本研究为1b期试验,采用mTPI设计,评估塞利尼索联合多柔比星在局部晚期/转移性软组织肉瘤患者中的安全性和疗效。常见≥3级药物相关不良事件为血液学毒性,包括中性粒细胞减少(56%)、发热性中性粒细胞减少(28%)和贫血(24%)。在24例可评估患者中,5例(21%)达到部分缓解,15例(63%)为疾病稳定。结论认为该联合方案在异质性软组织肉瘤患者中符合预设的耐受性边界。
要点
- 塞利尼索联合多柔比星在晚期软组织肉瘤中符合预设耐受性边界。
- 常见≥3级不良事件为血液学毒性,中性粒细胞减少发生率56%。
- 24例可评估患者中部分缓解率为21%,疾病稳定率为63%。
核心结论
- 在局部晚期/转移性软组织肉瘤患者中,塞利尼索联合多柔比星达到了预设的耐受性边界。
研究设计与样本
- 塞利尼索每周口服60或80 mg,联合多柔比星75 mg/m2静脉注射每21天一次。
- 6周期联合治疗后临床获益者接受塞利尼索维持治疗直至疾病进展或不可耐受毒性。
主要发现
- 最常见的≥3级药物相关不良事件为中性粒细胞减少(56%)、发热性中性粒细胞减少(28%)和贫血(24%)。
- 4例剂量限制性毒性均发生在80 mg剂量组,包括发热性中性粒细胞减少(2例)、呕吐和乏力。
- 24例可评估患者中,5例(21%)最佳疗效为部分缓解,15例(63%)为疾病稳定。
- 估计中位无进展生存期为5.5个月(95%CI:4.1-5.7),中位总生存期为10.5个月(95%CI:7.5-14)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selinexor is a first-in-class selective inhibitor of nuclear export (SINE) compound with single-agent activity in soft tissue sarcoma (STS). The study's aim was to determine the safety and efficacy of selinexor in combination with doxorubicin in patients with locally advanced/metastatic STS. METHODS: This phase 1b study used a mTPI design. Patients received selinexor at either 60 or 80 mg weekly PO plus doxorubicin (75 mg/m2 IV q21 days). Patients with clinical benefit (defined as ≥stable disease via RECIST 1.1) after six cycles of combination treatment received maintenance selinexor until disease progression or unacceptable toxicity. Disease assessments were conducted every two cycles. Pharmacokinetic data were collected on the first three patients per dose level. RESULTS: Twenty-five patients were enrolled (20 female, ECOG 0/1: 13/12, median age 57 years [range 21-74]). Disease subtypes included leiomyosarcoma (n = 6), malignant peripheral nerve sheath tumour (n = 3) and other sarcomas (n = 16). Three (12%) and 22 (88%) patients were treated at 60 mg and 80 mg of selinexor, respectively. The most common ≥G3 drug-related adverse events (AEs) were haematological, including neutropenia (56%), febrile neutropenia (28%) and anaemia (24%). There were four dose-limiting toxicities (febrile neutropenia (x2), vomiting, fatigue) all at the 80 mg dose level. There was one death secondary to heart failure. Of the 24 evaluable patients, 5 (21%) had a partial response and 15 (63%) had SD as best response. The estimated median progression-free survival (PFS) and overall survival (OS) were 5.5 (95% CI:4.1-5.7) and 10.5 (95% CI:7.5-14) months. CONCLUSION: In a heterogeneous group of patients with locally advanced/metastatic STS, the combination of selinexor and doxorubicin fulfilled the prespecified boundary for tolerability.
引用
- Lewin J, Malone E, Al-Ezzi E, et al. A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS). Eur J Cancer. 2021. PMID: 33418486. doi:10.1016/j.ejca.2020.10.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。